PURPOSE: We determined the impact of preexisting co-morbidities on survival of men with clinical stages T1b and T2NXM0 prostate cancer treated with surgery or radiation therapy. MATERIALS AND METHODS: A weighted co-morbidity score was determined for 276 consecutive men treated with surgery (138) or radiation therapy (138) at a Veterans Affairs medical center and was correlated with actuarial freedom from death due to co-morbid disease. RESULTS: After a median potential followup of 7.0 years 91 patients (33%) died of co-morbid disease and 20 (7%) died of cancer related causes. There were highly significant correlations between actuarial survival and weighted co-morbidity (p < 0.000001), and the 10-year actuarial survivals in men with no or severe co-morbidities were 66 and 9%, respectively. Associations between patient age and co-morbidity score were highly significant (p < 0.0001). The age adjusted risk of co-morbid death was 5.7 times greater in men with severe compared to no co-morbidities. There were also significant correlations between actuarial survival and weighted co-morbidity among patients treated with surgery (p = 0.02) and radiation therapy (p = 0.0002). Patient age and severity of co-morbidities were significantly greater among men treated with radiation therapy compared to surgery, and age adjusted risk of co-morbid death among men with a co-morbidity score of 1 was 3.8 times greater among men treated with radiation therapy (p = 0.025). CONCLUSIONS: Cancer related deaths are unusual within 5 to 10 years after surgery or radiation therapy in men with stages T1b and 2 prostate cancer. The risk of death during this interval is directly related to the severity of co-morbid conditions, which should be factored in an individual when assessing the advisability of therapeutic intervention. Since patient co-morbidities impact all cause survival, quantitative assessment of co-morbidities using validated instruments offers a method to control partially for the variabilities of health status among men receiving different treatments for localized prostate cancer.
PURPOSE: We determined the impact of preexisting co-morbidities on survival of men with clinical stages T1b and T2NXM0 prostate cancer treated with surgery or radiation therapy. MATERIALS AND METHODS: A weighted co-morbidity score was determined for 276 consecutive men treated with surgery (138) or radiation therapy (138) at a Veterans Affairs medical center and was correlated with actuarial freedom from death due to co-morbid disease. RESULTS: After a median potential followup of 7.0 years 91 patients (33%) died of co-morbid disease and 20 (7%) died of cancer related causes. There were highly significant correlations between actuarial survival and weighted co-morbidity (p < 0.000001), and the 10-year actuarial survivals in men with no or severe co-morbidities were 66 and 9%, respectively. Associations between patient age and co-morbidity score were highly significant (p < 0.0001). The age adjusted risk of co-morbid death was 5.7 times greater in men with severe compared to no co-morbidities. There were also significant correlations between actuarial survival and weighted co-morbidity among patients treated with surgery (p = 0.02) and radiation therapy (p = 0.0002). Patient age and severity of co-morbidities were significantly greater among men treated with radiation therapy compared to surgery, and age adjusted risk of co-morbid death among men with a co-morbidity score of 1 was 3.8 times greater among men treated with radiation therapy (p = 0.025). CONCLUSIONS:Cancer related deaths are unusual within 5 to 10 years after surgery or radiation therapy in men with stages T1b and 2 prostate cancer. The risk of death during this interval is directly related to the severity of co-morbid conditions, which should be factored in an individual when assessing the advisability of therapeutic intervention. Since patient co-morbidities impact all cause survival, quantitative assessment of co-morbidities using validated instruments offers a method to control partially for the variabilities of health status among men receiving different treatments for localized prostate cancer.
Authors: Grace L Lu-Yao; Peter C Albertsen; Dirk F Moore; Weichung Shih; Yong Lin; Robert S DiPaola; Siu-Long Yao Journal: JAMA Intern Med Date: 2014-09 Impact factor: 21.873
Authors: Claudio Jeldres; Nazareno Suardi; Paul Perrotte; Umberto Capitanio; Jochen Walz; Georg C Hutterer; Fred Saad; Luc Valiquette; Markus Graefen; Hugues Widmer; Pierre I Karakiewicz Journal: Can Urol Assoc J Date: 2009-02 Impact factor: 1.862
Authors: Michael A Liss; John Billimek; Kathryn Osann; Jane Cho; Ross Moskowitz; Adam Kaplan; Richard J Szabo; Sherrie H Kaplan; Sheldon Greenfield; Atreya Dash Journal: Cancer Date: 2013-04-25 Impact factor: 6.860
Authors: Timothy J Daskivich; Kang-Hsien Fan; Tatsuki Koyama; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Janet L Stanford; Antoinette M Stroup; Mark S Litwin; David F Penson Journal: Ann Intern Med Date: 2013-05-21 Impact factor: 25.391
Authors: Grace L Lu-Yao; Peter C Albertsen; Dirk F Moore; Weichung Shih; Yong Lin; Robert S DiPaola; Siu-Long Yao Journal: JAMA Date: 2008-07-09 Impact factor: 56.272
Authors: Laura Q Rogers; Kerry S Courneya; Rammarayan Paragi-Gururaja; Stephen J Markwell; Remi Imeokparia Journal: BMC Public Health Date: 2008-01-22 Impact factor: 3.295